With early approvals for a targeted cancer drug in Brazil and Argentina, this global pharmaceutical company was presented with an opportunity for an accelerated market launch. The team faced several important challenges – implementing a robust education strategy with payers on unmet medical need and a new clinical endpoint, as well as demonstrating the economic benefit of the treatment. They have partnered with BaseCase and Certara Evidence & Access to overcome these challenges. With an integrated Certara Evidence & Access and BaseCase workflow, the market access team was able to reduce their administrative workload and focus on developing a value story tool with an integrated Budget Impact Calculator. This interactive tool has offered an opportunity for a guaranteed consistency in presented value messages, endpoints, and disease prevalence data throughout the Latin American (LATAM) region for their drug.
Contact us